secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-064374
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports positive final Phase 2a data for CAN-2409 in NSCLC; mOS 24.5 months, long survival tail
--------------------------------------------------------------------------------

- mOS of 24.5 months in evaluable patients (cohort 1+2, n=46) with advanced NSCLC inadequately responding to ICI.
- In patients with progressive disease at baseline (cohort 2, n=41), mOS was 21.5 months, vs. 9.8–11.8 months for docetaxel.
- 37% (15/41) of progressive disease patients alive >24 months; long tail of survival observed.
- In non-squamous NSCLC (n=33), mOS was 25.4 months; ITT analysis showed 16.7 months vs. 9.9–12.3 months for SOC.
- Systemic anti-tumor response (abscopal effect) seen in 69% of patients with multiple lesions; safety profile favorable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525064374/0001193125-25-064374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525064374/d917988d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-064374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer